Free Trial
→ Buffett's Final Warning: 'The Dollar Is Going to Hell' (From Decentralized Masters) (Ad)tc pixel
NASDAQ:CORT

Corcept Therapeutics Q3 2026 Earnings Date & Estimates

Corcept Therapeutics logo
$117.80 -3.39 (-2.80%)
Closing price 04:00 PM Eastern
Extended Trading
$117.20 -0.59 (-0.51%)
As of 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corcept Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for November 3, 2026 at 5:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
5:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Corcept Therapeutics in Q3 2026

Corcept Therapeutics is expected to post earnings of $0.8130 per share on revenue of $323.90 million. In the same quarter a year earlier Corcept Therapeutics reported $0.16 per share on revenue of $207.64 million. Corcept Therapeutics last reported on July 29, 2026, posting $0.36 per share and beating the $0.0243 consensus estimate. Corcept Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.8130
Expected Revenue
$323.90 million
Prior-Year EPS
$0.16
Prior-Year Revenue
$207.64 million
Expected EPS Growth
+408.1%
Expected Revenue Growth
+56.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.36 (Beat by +$0.3357)
Last Quarter Revenue
$256.15 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Corcept Therapeutics Q3 2026 Earnings FAQ

Corcept Therapeutics (NASDAQ:CORT) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Corcept Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Corcept Therapeutics to post earnings of $0.8130 per share for Q3 2026.

The consensus revenue estimate for Corcept Therapeutics is $323.90 million for Q3 2026.

Corcept Therapeutics Earnings Headlines

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Has Consensus Price Target of $138.17
October 13 at 5:16 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114302
Head to Head Analysis: Cronos Group (NASDAQ:CRON) & Corcept Therapeutics (NASDAQ:CORT)
October 13 at 4:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114228
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
October 13 at 1:00 AM  |  Stansberry Research (Ad)
Drugmaker Corcept seeks to bar ex-judge's views in Teva antitrust case
October 12 at 5:42 PM  |  reuters.comhttps://www.reuters.com/legal/litigation/drugmaker-corcept-seeks-bar-ex-judges-views-teva-antitrust-case-2026-10-12/
Head to Head Survey: Corcept Therapeutics (NASDAQ:CORT) versus Ovid Therapeutics (NASDAQ:OVID)
October 10 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104709
Corcept Therapeutics (NASDAQ:CORT) Stock: Insider Joseph Douglas Lyon Sells 810 Shares
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095486
See More Corcept Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Corcept Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corcept Therapeutics and other key companies, straight to your email.

About Corcept Therapeutics

Corcept Therapeutics (NASDAQ:CORT) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol activity in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s principal commercial product is Korlym (mifepristone), a glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have had unsuccessful surgery. The company also develops investigational therapies intended to selectively block cortisol’s effects while preserving other functions of the glucocorticoid receptor.

Corcept was founded in 1998 and is headquartered in Menlo Park, California. Its commercial focus has historically been the United States, where Korlym is marketed, while its research and development programs address potential applications in several therapeutic areas. Joseph K. Belanoff, a co-founder, has served as the company’s chief executive officer.

View Corcept Therapeutics Profile
Earnings Tools